Related Party Transactions	12 Months Ended
Dec. 31, 2022
Related Party Transactions
Related Party Transactions	20. Related Party Transactions As of December 31, 2022, Vifor International owned 7,396,770, or 13.7%, of the Company’s common stock. CSL Vifor and its affiliates are considered related parties as of December 31, 2022 and 2021 (see Note 12, Collaboration and Licensing Agreements). As of December 31, 2022, amounts due from CSL Vifor of $3,260 primarily relating to the Company’s share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor and its commercial supply of KORSUVA injection to CSL Vifor were included within accounts receivable, net – related party. The Company’s collaborative revenue of $16,572 from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the year ended December 31, 2022. The Company’s $15,000 milestone payment received from CSL Vifor for the approval of Kapruvia in April 2022 was included within license and milestone fees revenue for the year ended December 31, 2022. The Company’s $15,000 milestone payment received from CSL Vifor for the approval of KORSUVA injection in August 2021, and the $5,031 of premium from Vifor International’s purchase of the Company’s common stock were included within license and milestone fees revenue for the year ended December 31, 2021. Sales of KORSUVA injection to CSL Vifor of $10,223 and $701 were included within commercial supply revenue for the years ended December 31, 2022 and 2021, respectively. The associated COGS for the Company’s commercial supply revenue from CSL Vifor was $7,266 for the year ended December 31, 2022. Royalty revenue from the net sales of Kapruvia in Europe of $72 were included within royalty revenue for the year ended December 31, 2022. Sales of clinical compound to CSL Vifor for $361 were included within clinical compound revenue for the year ended December 31, 2021.

Related Party Transactions

12 Months Ended

Dec. 31, 2022

20. Related Party Transactions

As of December 31, 2022, Vifor International owned 7,396,770, or 13.7%, of the Company’s common stock. CSL Vifor and its affiliates are considered related parties as of December 31, 2022 and 2021 (see Note 12, Collaboration and Licensing Agreements).

As of December 31, 2022, amounts due from CSL Vifor of $3,260 primarily relating to the Company’s share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor and its commercial supply of KORSUVA injection to CSL Vifor were included within accounts receivable, net – related party.

The Company’s collaborative revenue of $16,572 from its share of the profit generated by sales of KORSUVA injection in the United States by CSL Vifor was included within collaborative revenue for the year ended December 31, 2022.

The Company’s $15,000 milestone payment received from CSL Vifor for the approval of Kapruvia in April 2022 was included within license and milestone fees revenue for the year ended December 31, 2022. The Company’s $15,000 milestone payment received from CSL Vifor for the approval of KORSUVA injection in August 2021, and the $5,031 of premium from Vifor International’s purchase of the Company’s common stock were included within license and milestone fees revenue for the year ended December 31, 2021.

Sales of KORSUVA injection to CSL Vifor of $10,223 and $701 were included within commercial supply revenue for the years ended December 31, 2022 and 2021, respectively. The associated COGS for the Company’s commercial supply revenue from CSL Vifor was $7,266 for the year ended December 31, 2022.

Royalty revenue from the net sales of Kapruvia in Europe of $72 were included within royalty revenue for the year ended December 31, 2022.

Sales of clinical compound to CSL Vifor for $361 were included within clinical compound revenue for the year ended December 31, 2021.